Literature DB >> 21590365

Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do?

Cliona Grant1, Kieron Dunleavy, Franziska C Eberle, Stefania Pittaluga, Wyndham H Wilson, Elaine S Jaffe.   

Abstract

In recent years, an overlap in biologic and clinical features has been identified between classic Hodgkin lymphoma (CHL) and primary mediastinal large B-cell lymphoma (PMBL). Further strengthening this relationship is the identification of lymphomas with clinical and morphologic features transitional between the two, known as gray zone lymphomas (GZL). However, this diagnostic gray zone is not just of theoretical interest: it presents a practical problem, as the treatment approaches for CHL traditionally differ from those for aggressive B-cell lymphomas. This article reviews the treatment approach for mediastinal lymphomas, including CHL of the nodular sclerosis subtype (CHL-NS), PMBL, and mediastinal GZL. Though several trials have evaluated different regimens with or without radiation in PMBL and CHL-NS, there is a lack of prospective experience in treating GZL because of the rarity of these tumors. Historical data indicate that they have done poorly with traditional approaches developed for the treatment of either CHL or diffuse large B-cell lymphoma.

Entities:  

Mesh:

Year:  2011        PMID: 21590365      PMCID: PMC6324553          DOI: 10.1007/s11899-011-0090-1

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  46 in total

1.  Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription.

Authors:  H Stein; T Marafioti; H D Foss; H Laumen; M Hummel; I Anagnostopoulos; T Wirth; G Demel; B Falini
Journal:  Blood       Date:  2001-01-15       Impact factor: 22.113

2.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

3.  Primary mediastinal clear cell lymphoma of B-cell type.

Authors:  P Möller; B Lämmler; M Eberlein-Gonska; G E Feichter; W J Hofmann; H Schmitteckert; H F Otto
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

4.  Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Franziska C Eberle; Jaime Rodriguez-Canales; Lai Wei; Jeffrey C Hanson; J Keith Killian; Hong-Wei Sun; Lisa G Adams; Stephen M Hewitt; Wyndham H Wilson; Stefania Pittaluga; Paul S Meltzer; Louis M Staudt; Michael R Emmert-Buck; Elaine S Jaffe
Journal:  Haematologica       Date:  2011-04       Impact factor: 9.941

5.  Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy.

Authors:  O W Kamel; L M Weiss; M van de Rijn; T V Colby; D W Kingma; E S Jaffe
Journal:  Am J Surg Pathol       Date:  1996-10       Impact factor: 6.394

6.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

Authors:  Kerry J Savage; Stefano Monti; Jeffery L Kutok; Giorgio Cattoretti; Donna Neuberg; Laurence De Leval; Paul Kurtin; Paola Dal Cin; Christine Ladd; Friedrich Feuerhake; Ricardo C T Aguiar; Sigui Li; Gilles Salles; Francoise Berger; Wen Jing; Geraldine S Pinkus; Thomas Habermann; Riccardo Dalla-Favera; Nancy Lee Harris; Jon C Aster; Todd R Golub; Margaret A Shipp
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

7.  Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma.

Authors:  Christina B Hertel; Xiao-ge Zhou; Stephen J Hamilton-Dutoit; Steffen Junker
Journal:  Oncogene       Date:  2002-07-25       Impact factor: 9.867

8.  Hodgkin's disease during HIV1 infection: the French registry experience. French Registry of HIV-associated Tumors.

Authors:  J M Andrieu; S Roithmann; J M Tourani; R Levy; B Desablens; C le Maignan; J A Gastaut; P Brice; M Raphael; B Taillan
Journal:  Ann Oncol       Date:  1993-09       Impact factor: 32.976

9.  Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

Authors:  Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans-Konrad Müller-Hermelink; Eckhardt Dühmke; Markus Loeffler
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

10.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more
  15 in total

1.  Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.

Authors:  Min Shi; Margaretha G M Roemer; Bjoern Chapuy; Xiaoyun Liao; Heather Sun; Geraldine S Pinkus; Margaret A Shipp; Gordon J Freeman; Scott J Rodig
Journal:  Am J Surg Pathol       Date:  2014-12       Impact factor: 6.394

2.  A prospective study of mediastinal gray-zone lymphoma.

Authors:  Wyndham H Wilson; Stefania Pittaluga; Alina Nicolae; Kevin Camphausen; Margaret Shovlin; Seth M Steinberg; Mark Roschewski; Louis M Staudt; Elaine S Jaffe; Kieron Dunleavy
Journal:  Blood       Date:  2014-07-14       Impact factor: 22.113

3.  Primary splenic B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: A case report.

Authors:  Feng Shi; Quan Zhou; Ying Gao; Xiang-Qing Cui; Hong Chang
Journal:  Oncol Lett       Date:  2016-07-11       Impact factor: 2.967

Review 4.  Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies.

Authors:  Kieron Dunleavy
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

5.  Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.

Authors:  Monika Pilichowska; Stefania Pittaluga; Judith A Ferry; Jessica Hemminger; Hong Chang; Jennifer A Kanakry; Laurie H Sehn; Tatyana Feldman; Jeremy S Abramson; Athena Kritharis; Francisco J Hernandez-Ilizaliturri; Izidore S Lossos; Oliver W Press; Timothy S Fenske; Jonathan W Friedberg; Julie M Vose; Kristie A Blum; Deepa Jagadeesh; Bruce Woda; Gaurav K Gupta; Randy D Gascoyne; Elaine S Jaffe; Andrew M Evens
Journal:  Blood Adv       Date:  2017-12-11

6.  Histopathological difficulties in an adolescent lymphoma patient.

Authors:  Ferenc Magyari; Sándor Barna; Zsófia Miltényi; Hajnalka Rajnai; Judit Csomor; Miklós Udvardy; Árpad Illés; László Váróczy
Journal:  Pathol Oncol Res       Date:  2014-07-02       Impact factor: 3.201

7.  Monoamine oxidase A is highly expressed in classical Hodgkin lymphoma.

Authors:  Pei Chuan Li; Imran N Siddiqi; Anja Mottok; Eric Y Loo; Chieh Hsi Wu; Wendy Cozen; Christian Steidl; Jean Chen Shih
Journal:  J Pathol       Date:  2017-09-05       Impact factor: 7.996

Review 8.  Diffuse large B-cell lymphoma-treatment approaches in the molecular era.

Authors:  Mark Roschewski; Louis M Staudt; Wyndham H Wilson
Journal:  Nat Rev Clin Oncol       Date:  2013-11-12       Impact factor: 66.675

9.  CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications.

Authors:  Matthew W Anderson; Shuchun Zhao; Aharon G Freud; Debra K Czerwinski; Holbrook Kohrt; Ash A Alizadeh; Roch Houot; Denize Azambuja; Irene Biasoli; José Carlos Morais; Nelson Spector; Hernan F Molina-Kirsch; Roger A Warnke; Ronald Levy; Yasodha Natkunam
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

Review 10.  The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification.

Authors:  Madhu P Menon; Stefania Pittaluga; Elaine S Jaffe
Journal:  Cancer J       Date:  2012 Sep-Oct       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.